OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← Jnetics

2024-12-31-accounts

JNETICS

(A Company Limited by Guarantee)

DIRECTORS’ REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

Page
Legal and Administrative details 3
Directors’ Report 4-7
Independent auditor’s report 8-10
Statement of Financial Activities 11
Balance Sheet 12
Statement of Cash flows 13
Notes to the Financial Statements 14-20

2

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

Directors & Trustees: A L Angel
A M Leon
L Blitz
Dr M Ziff
E May
Dr J Harris
N Goldschneider (resigned 15 July 2024)
A H Freinkel (appointed 24 March 2025)
J M Krell (appointed 24 March 2025)
Registered Office: 505 Centennial Park, Centennial Avenue,
Elstree WD6 3FG
Independent auditor: Goldwins Limited, Chartered Accountants
75 Maygrove Road,
West Hampstead, London, NW6 2EG
Bankers: Barclays Bank UK Plc
1 Churchill Place
London E14 5HP
Charity registration number: 1134935
Company registration number: 07087270

3

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

TRUSTEES / DIRECTORS’ REPORT

Principal Activities and Charitable Objectives

The charity is established for the following purposes:

In establishing the activities of the charity, the directors have given due consideration to the Charity Commission's guidance regarding the provision of public benefit.

Achievements and Performance

In January 2024, following a highly successful pilot, the NHS Jewish BRCA Testing Programme was officially launched, Jnetics and Chai Cancer Care, deliver the engagement campaign. The launch event, held at the House of Lords, was attended by prominent community leaders, Members of Parliament, and representatives from key national charities. The PR and media coverage generated from the event far exceeded expectations, resulting in over 25,000 individuals registering for screening by the end of December 2024.

The programme has sharpened Jnetics’ focus on hereditary cancers and reinforced our position as the primary point of contact for the Jewish community for information and screening related to both recessive and dominant genetic conditions. In April 2024, following a competitive bidding process, — Jnetics- again working closely with Chai Cancer Care was reappointed as the official engagement partner for the NHS programme until April 2026.

On the fundraising front, given the relatively small size of our organisation, the demands on the community, and the challenge of holding a major fundraising event (such as a matched funding campaign or major dinner) every year, the charity has now adopted a two-year budgeting strategy. We have also broadened our focus to cover several smaller annual events targeted at specific audiences. This is helping to diversify our income sources which is important as, whilst 2024 is a year in which we did hold a major event, in 2025 we do not plan to do so.

The first half of 2024 progressed as expected, with a quieter period in line with the community’s shift in attention toward Israel and Israel-based charities. However, the final quarter saw the launch of our third matched funding campaign, which raised £754,210 and brought in over 2,000 new donors. This vital support enables us to deliver on our dual mission: to prevent the birth of children affected by the severe genetic conditions we test for, and to improve the prevention, diagnosis, and management of Jewish genetic disorders.

Further highlights of 2024 included:

4

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

All three of our recessive screening programmes experienced growth in 2024.

Despite the Jnetics Clinic being closed from January to March, due to the introduction of the new nonappointment-based clinic model and a move to our new genetic counselling supplier, CRGH, we saw — significant year-on-year growth screening 423 individuals compared to 342 in 2023. This increase is largely attributable to the transition to a more efficient screening model.

Our Campus Screening Programme continued its upward trend, with 305 students screened in the 2023/24 academic year compared to 244 the previous year.

The Schools Programme saw exceptional growth, screening 521 Year 12 students, up from 356 in 2022/23. In addition to maintaining our presence in all eight mainstream Jewish secondary schools, we expanded our programme further into non-Jewish schools with significant numbers of Jewish students, further broadening our reach.

The virtual format of both the clinic and university programmes has enabled us to reach more individuals across a wider geographic area, improving convenience and reducing both cost and time. Only the Schools Programme remains fully in-person, allowing us to maintain the educational component that is integral to its success and an important long-term aim of Jnetics.

In 2024, following extensive stakeholder consultation, we approved and adopted a new three-year strategic plan. This plan will enable Jnetics to build on our strong foundations to improve delivery, increase efficiency and effectiveness, and fully leverage opportunities arising from our expanded screening panel and increased focus on hereditary cancers.

Plans for Future Periods

The first three months of 2025 have delivered impressive results across all three of our recessive screening programmes. These strong early numbers position the charity well to exceed our target of screening 1,400 young adults in 2025 (compared to 1,250 in 2024).

In May, the charity held its third annual Ladies Event, which proved to be a major success. Attendance rose significantly to 200 guests (from 154 in 2024), and the event generated increased funds while also introducing many new supporters to the work of Jnetics. This event is now firmly established as a key fixture in our annual fundraising calendar.

Our Young Professionals Committee continues to thrive and grow, helping to amplify our message — among a crucial demographic. A diverse programme of events is planned throughout 2025 including — a fine dining experience, a film screening, and a supper quiz to keep this important audience engaged and connected to our mission.

The second half of 2025 will see a continuation of existing awareness activities and the launch of new initiatives. These efforts will support the expansion of our donor database and help attract new supporters. In Q4 2025, we plan to reintroduce a Business Breakfast aimed at the growing interest of our supporter base in a wide range of genetic issues and engaging a new professional audience. Additional events in our well-established Scientific Lecture Series will further address this interest and have help ed to develop Jnetics’ reputation as a credible and respected voice in the medical and scientific communities. We will also expand our challenges portfolio by introducing one new challenge

5

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

event during 2025 appealing to a different target market. The Jnetics annual Golf Day, scheduled for September, has already reached full capacity.

A major focus for the latter half of the year will be working closely with NHS England to ensure the continued delivery of BRCA screening for the Jewish community following the planned closure of the — NHS Jewish BRCA testing programme in April 2025. A seamless transition to a new delivery model — underpinned by strong and ongoing community engagement is vital to maintaining public confidence and continuity of care.

Looking ahead, we will continue to build on the charity’s strong foundations to improve delivery, efficiency, and impact. We have strengthened our Scientific and Medical Advisory Board and are delighted now to have a significantly broader range of expert skills on which to draw. With their guidance, we see significant potential in careful expansion of our recessive screening panel and advancing our work around hereditary cancers. In line with growing demand across our programmes, we anticipate a need to invest in the growth of the Jnetics team, enabling us to deliver on our core objectives with greater capacity and effectiveness.

— — Continued engagement with and support from the community remains central to our success. Encouragingly, we are seeing increased awareness within the community around JGDs and the crucial role Jnetics plays in prevention and education.

Financial review

Principal sources of funding

The charity receives most of its funding from donations and was able to claim gift aid where applicable.

Results for the year

The financial statements for the year are set out in pages 11 to 20. The Statement of Financial Activities on page 11 reflects a surplus of £398,720 (2023- surplus of £240,854) for the year ending 2024.

Reserves

The charity aims to maintain free reserves sufficient to finance its operating costs for around 6 months. Reserves in excess of this amount are applied to further the charity's objectives. The charity's reserves at 31 December 2024 amounted to £860,909 (2023 - £462,189), of which £841,089 (2023 - £437,569) related to unrestricted funds.

As stated above, the charity has adopted a 2-year income strategy, and it is anticipated that the modest reserves in 2024 over and above the 6 months approved by the Trustees will be used to cover a projected shortfall in 2025.

Structure, Governance and Management

Jnetics ("the charity") is a company limited by guarantee (No.07087270) and a recognised English charity (No. 1134935), governed by its Memorandum and Articles of Association. The charity was incorporated as Jewish Genetic Disorders UK on 25 November 2009 and changed its name to Jnetics on 2 July 2015.

Appointment of Directors

New Directors are nominated for appointment and appointed by the existing Directors until Jnetics next Annual General Meeting. If confirmed, they serve until the Annual General Meeting at least three years after appointment and, subject to reappointment.

Prior to their appointment, new Directors would be familiar with the charity's values, its aims and objectives and its day-to-day operations.

6

JNETICS (A Company Limited by Guarantee) FOR THE YEAR ENDED 31 DECEMBER 2024

As part of their induction programme, new Directors are required to understand their statutory Responsibilities.

Statement on Risk

The Directors are assessing the major risks to which the charity is exposed on an ongoing basis and are establishing procedures to mitigate those that are identified as a result of these reviews.

Office Bearers

The Directors who served during the year and to the date of this report were as follows:

A L Angel A M Leon L Blitz Dr M Ziff E May Dr J Harris N Goldschneider (resigned 15 July 2024) A H Freinkel (appointed 24 March 2025) J M Krell (appointed 24 March 2025)

Trustees / Directors’ responsibilities

Company Law which is also applicable to charitable companies in England and Wales requires the directors, who are also Trustees of the company, to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the results of the company for that year.

In preparing those financial statements, the directors/Trustees are required to:

The directors/Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company exemptions

The above report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the Board of Trustees / Directors on …………… 28 July 2025 and signed on its behalf by:

A L Angel Director and Chair

7

)25 :+,&+

$1'

6

25

11/08/2025

==> picture [247 x 33] intentionally omitted <==

----- Start of picture text -----
%37897.(9) "897.(9) $49&1 '9>+6
+:3)8 +:3)8 +:3)8 0?8.=
? ? ? D
----- End of picture text -----

==> picture [192 x 8] intentionally omitted <==

----- Start of picture text -----
? ? D D
----- End of picture text -----

'2/ 038+8-3+6 =>+>/7/8>= 2+@/ ,//8 :</:+</. 38 +--9<.+8-/ A3>2 >2/ =:/-3+6 :<9@3=398= 09< =7+66 -97:+83/= ?8./<

Approved by the trustees on .. 28 July 2025 ~~..........ee~~

$7:89**

==> picture [250 x 451] intentionally omitted <==

----- Start of picture text -----
& 275,058 241,225
(260) (28,768)
(260) (28,768)
274,798 212,457
651,246 438,789
' 926,044 651,246
? D
398,720 240,854
9,886 5,836
(69,632) (22,321)
(63,916) 16,856
275,058 241,225
At 1 At
January 9-7 31 December
2024 Cash flows (-&3,8 2024
D ? ? ?
----- End of picture text -----

�3*9.(8

�498�94�9-�+.3&3(.&1�89&92398

�47�9-�>&7�3))� ��(2'*7�

�((4:39.3,�541.(.*8

&� �&8.8�4+�57*5&7&9.43

'2/ -2+<3>+,6/ -97:+8C 7//>= >2/ ./0383>398 90 + :?,63- ,/8/03> /8>3>C ?8./< �%& �==/>= +8. 63+,363>3/= +</ 383>3+66C </-9183=/.�+>�23=>9<3-+6�-9=>�9<�><+8=+->398�@+6?/�?86/==�9>2/+>/.�38�>2/�/6/@+8�+--9?8>381�:963-C�9<�89>/

'��4.3,�(43(*73

�8-97/ 0<97 19@/<87/8> +8. 9>2/< 1<+8>=�A2/>2/< 1<+8>= 9< 1<+8>=�3= </-9183=/. A2/8 >2/ -2+<3>C 2+= /8>3>6/7/8> >9 >2/ 0?8.=�+8C :/<09<7+8-/ -98.3>398= +>>+-2/. >9 >2/ 1<+8>= 2+@/ ,//8 7/>�3> 3= :<9,+,6/ >2+> >2/ 38-97/ A366 ,/ </-/3@/. +8. >2/ +79?8> -+8 ,/ 7/+=?</. </63+,6C +8. 3= 89> ./0/<</. �8-97/ </-/3@/. 38 +.@+8-/ 09< >2/ :<9@3=398 90 =:/-303/. =/<@3-/�3=�./0/<</.�?8>36�>2/�-<3>/<3+�09<�38-97/�</-9183>398�+</�7/>

)��39789�7(*.;&'1

,��114(&9.43�4+�8:55479�(4898

-� $&3,.'1�+.=)�&88*98

�97:?>/<�/;?3:7/8> �C/+<=�=><+312>�638/ �?<83>?</�+8.��3>>381= ��C/+<=�=><+312>�638/

.� �*'9478

'<+./ +8. 9>2/< ./,>9<= +</ </-9183=/. +> >2/ =/>>6/7/8> +79?8> .?/ +0>/< +8C ><+./ .3=-9?8> 900/</. $</:+C7/8>= +</ @+6?/. +>�>2/�+79?8>�:</:+3.�8/>�90�+8C�><+./�.3=-9?8>=�.?/

/� �&8-�&9�'&30�&3)�.3�-&3)

0� �7*).9478�&3)�574;.8.438

�

(8</=><3->/. %/=><3->/. '9>+6 0?8.= 0?8.= 0?8.= D D D

%37897.(9) "897.(9) $49&1 '9>+6 +:3)8 +:3)8 +:3)8 0?8.= ? ? ? D 37,782 - 37,782 44,062 71,140 - 71,140 56,275 108,922 - 108,922 100,337 %37897.(9) "897.(9) $49&1 '9>+6 +:3)8 +:3)8 +:3)8 0?8.= ? ? ? D 850,999 254,855 1,105,854 900,736 36,928 - 36,928 40,077 88,640 - 88,640 68,921 - - - 1,038 58,245 - 58,245 - 7,034,872 254,855 1,289,667 010,772 %37897.(9) "897.(9) $49&1 '9>+6 +:3)8 +:3)8 +:3)8 0?8.= ? ? ? D

~~Charitable~~ #:55479 (4898 &(9.;.9.*8 (4898 $49&1 '9>+6 ? ? ? ? D

&-<//8381

'/6/:298/ $9=> &?8.<C

&?,=-<3:>398=

!//>381 '<+@/6

~~Fundraising~~ ~~Charitable~~
~~Fundraising~~ ~~Charitable~~ &?::9<>
-9=>= +->3@3>3/= -9=>= '9>+6
D D D D

&-<//8381

'/6/:298/ $9=> &?8.<C

&?,=-<3:>398=

!//>381 '<+@/6

? D 5,836 4,000 ? D

'2/ >9>+6 /7:69C// ,/8/03>= 38-6?.381 Employer's NIC and :/8=398 -98><3,?>398= 90 >2/ 5/C 7+8+1/7/8> :/<=988/6 A/</

"9 -2+<3>C ><?=>//= A/</ :+3. 9< </-/3@/. +8C 9>2/< ,/8/03>= 0<97 /7:69C7/8> A3>2 >2/ -2+<3>C 38 >2/ C/+<

"9

$&=&9.43

03>>381= Equipment $49&1 D D ?

==> picture [46 x 84] intentionally omitted <==

----- Start of picture text -----
$</:+C7/8>=
Creditors:
Trade
Taxation and
$/8=398
----- End of picture text -----

==> picture [140 x 377] intentionally omitted <==

----- Start of picture text -----
? D
14,654 5,076
- -
78,398 9,422
10,602 19,524
103,654 34,022
? D
80,597 189,583
7,913 7,685
1,566 1,308
88,120 21,000
8,198 30,734
186,394 250,310
? D
- 3,000
- (3,000)
- -
for the purpose of projects which
subsequent year.
%37897.(9) "897.(9) $49&1
+:3)8 +:3)8 +:3)8
? ? ?
17,605 - 17,605
823,484 19,820 843,304
841,089 19,820 860,909
(8</=><3->/. %/=><3->/. '9>+6
0?8.= 0?8.= 0?8.=
D D D
----- End of picture text -----

==> picture [35 x 8] intentionally omitted <==

----- Start of picture text -----
&-<//8381
----- End of picture text -----

==> picture [205 x 183] intentionally omitted <==

----- Start of picture text -----
Incoming :9,4.3,
resources & resources & At the end
,&.38 14888 $7&38+78 of the year
? ? ? ? ?
167,355 (172,155) - 19,820
- 55,000 (55,000) - -
- 32,500 (32,500) - -
254,855 (259,655) - 19,820
1,151,289 (747,769) - 841,089
1,151,289 (747,769) - 841,089
Incoming #?>19381
resources & resources & At the end
1+38= 69==/= '<+8=0/<= of the year
D D D D D
----- End of picture text -----

==> picture [414 x 118] intentionally omitted <==

----- Start of picture text -----
'9 0?8. + :<94/-> >9 ./@/69: 5/C 3809<7+>398 </=9?<-/= +8. <+3=/ +A+</8/== </6+>381 >9 BRCA associated -+8-/<= +7981
>2/ ‘at 38-</+=/. risk' Jewish :9:?6+>398 38 >2/ UK with >2/ +37 90 37:<9@381 >2/ awareness, diagnosis +8. 7+8+1/7/8> 90
these cancers.
Legal status of the charity
'2/ -2+<3>C 3= + -97:+8C 6373>/. ,C 1?+<+8>// +8. 2+= 89 =2+</ capital. Each 7/7,/< 3= 63+,6/ >9 -98><3,?>/ + =?7 89>
exceeding £1 in the event of the charity being wound up.
Related party transactions
During >2/ year, the -2+<3>C </-/3@/. + >9>+6 90 £36,250 in .98+>398= (£18,016 in 2023) from >2/ ><?=>//= +8. 0<97 9>2/<
----- End of picture text -----